Clinical Trials
299 trialsNCT04938817 2026-05-27
KEYNOTE-B98
Merck Sharp & Dohme LLC
Phase 1/2 Active not recruiting
NCT05593094 2026-05-26
A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors
Hoffmann-La Roche
Phase 1/2 Active not recruiting
NCT06188702 2026-05-26
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
Servier
Phase 1/2 Active not recruiting
NCT05682443 2026-05-22
PRESERVE-006
OncoC4, Inc.
Phase 1/2 Active not recruiting
NCT05736406 2026-05-22
A Dose-escalation Clinical Study of Intraoperative Photodynamic Therapy of Glioblastoma
Hemerion Therapeutics
Phase 1/2 Active not recruiting
NCT06084884 2026-05-22
ATHENA
AstraZeneca
Phase 1/2 Active not recruiting
NCT06305247 2026-05-20
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
Ipsen
Phase 1/2 Active not recruiting
NCT05726864 2026-05-19
AMPLIFY-7P
Elicio Therapeutics
Phase 1/2 Active not recruiting
NCT07280377 2026-05-19
GOBLET
Oncolytics Biotech
Phase 1/2 Active not recruiting
NCT04626479 2026-05-18
MK-3475-03A
Merck Sharp & Dohme LLC
Phase 1/2 Active not recruiting
NCT04661007 2026-05-18
J-MIND
Incyte Corporation
Phase 1/2 Active not recruiting
NCT06359041 2026-05-18
RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
Cabaletta Bio
Phase 1/2 Active not recruiting
NCT04068610 2026-05-15
COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC
MedImmune LLC
Phase 1/2 Active not recruiting
NCT07134088 2026-05-15
A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia
Amgen
Phase 1/2 Active not recruiting
NCT04067336 2026-05-13
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
Kura Oncology, Inc.
Phase 1/2 Active not recruiting
NCT05099172 2026-05-13
First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
Bayer
Phase 1/2 Active not recruiting
NCT05438329 2026-05-12
First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors
DualityBio Inc.
Phase 1/2 Active not recruiting
NCT04152499 2026-05-11
MK-2870-001
Klus Pharma Inc.
Phase 1/2 Active not recruiting
NCT05661955 2026-05-11
A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.
BeOne Medicines
Phase 1/2 Active not recruiting
NCT06162572 2026-05-11
Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)
Servier
Phase 1/2 Active not recruiting
NCT02908906 2026-05-08
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers
Janssen Research & Development, LLC
Phase 1/2 Active not recruiting
NCT04817007 2026-05-08
A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)
Bristol-Myers Squibb
Phase 1/2 Active not recruiting
NCT05265091 2026-05-08
A Study of KL590586 in Patients With Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1/2 Active not recruiting
NCT05488314 2026-05-08
METalmark
Janssen Research & Development, LLC
Phase 1/2 Active not recruiting
NCT05535244 2026-05-07
CAMMA 2
Hoffmann-La Roche
Phase 1/2 Active not recruiting
NCT04083599 2026-05-06
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Genmab
Phase 1/2 Active not recruiting
NCT04126200 2026-05-06
DREAMM 5
GlaxoSmithKline
Phase 1/2 Active not recruiting
NCT04626518 2026-05-06
KEYMAKER-U03
Merck Sharp & Dohme LLC
Phase 1/2 Active not recruiting
NCT05164094 2026-05-06
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults
ModernaTX, Inc.
Phase 1/2 Active not recruiting
NCT06125522 2026-05-06
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)
Pfizer
Phase 1/2 Active not recruiting
NCT07084896 2026-05-06
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM
GlaxoSmithKline
Phase 1/2 Active not recruiting
NCT02029443 2026-05-05
ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia
Acerta Pharma BV
Phase 1/2 Active not recruiting
NCT03625037 2026-05-05
EPCOREâ„¢ NHL-1
Genmab
Phase 1/2 Active not recruiting
NCT04542824 2026-05-05
EPCOREâ„¢ NHL-3
Genmab
Phase 1/2 Active not recruiting
NCT04623541 2026-05-05
EPCOREâ„¢ CLL-1
Genmab
Phase 1/2 Active not recruiting
NCT04663347 2026-05-05
EPCOREâ„¢ NHL-2
Genmab
Phase 1/2 Active not recruiting
NCT04896697 2026-05-05
Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors
Xilio Development, Inc.
Phase 1/2 Active not recruiting
NCT05067140 2026-05-05
A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer
Novartis
Phase 1/2 Active not recruiting
NCT05083481 2026-05-05
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
Astellas Pharma Inc
Phase 1/2 Active not recruiting
NCT05271318 2026-05-05
PROTA
TILT Biotherapeutics Ltd.
Phase 1/2 Active not recruiting
NCT07026279 2026-05-05
A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer
Amplia Therapeutics Limited
Phase 1/2 Active not recruiting
NCT02343042 2026-05-04
STOMP
Karyopharm Therapeutics Inc
Phase 1/2 Active not recruiting
NCT03393884 2026-05-04
OVATION 2
Imunon
Phase 1/2 Active not recruiting
NCT03491683 2026-05-04
INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)
Inovio Pharmaceuticals
Phase 1/2 Active not recruiting
NCT05933265 2026-05-04
Study of LP-184 in Patients With Advanced Solid Tumors
Lantern Pharma Inc.
Phase 1/2 Active not recruiting
NCT06035497 2026-05-01
A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)
Bristol-Myers Squibb
Phase 1/2 Active not recruiting
NCT03075696 2026-04-30
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
Hoffmann-La Roche
Phase 1/2 Active not recruiting
NCT05983198 2026-04-29
SatisfACtion
Novartis
Phase 1/2 Active not recruiting
NCT04181788 2026-04-27
Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies
Pfizer
Phase 1/2 Active not recruiting
NCT03742102 2026-04-24
BEGONIA
AstraZeneca
Phase 1/2 Active not recruiting